Rajagopal G, Suresh V, Sachan Alok
Department of Endocrinology and Metabolism, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh - 517 507, India .
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S236-8. doi: 10.4103/2230-8210.104048.
The high-density lipoprotein cholesterol (HDL-C) is considered anti-atherogenic good cholesterol. It is involved in reverse transport of lipids. Epidemiological studies have found inverse relationship of HDL-C and coronary heart disease (CHD) risk. When grouped according to HDL-C, subjects having HDL-C more than 60 mg/dL had lesser risk of CHD than those having HDL-C of 40-60 mg/dL, who in turn had lesser risk than those who had HDL-C less than 40 mg/dL. No upper limit for beneficial effect of HDL-C on CHD risk has been identified. The goals of treating patients with low HDL-C have not been firmly established. Though many drugs are known to improve HDL-C concentration, statins are proven to improve CHD risk and mortality. Cholesteryl ester transfer protein (CETP) is involved in metabolism of HDL-C and its inhibitors are actively being screened for clinical utility. However, final answer is still awaited on CETP-inhibitors.
高密度脂蛋白胆固醇(HDL-C)被认为是具有抗动脉粥样硬化作用的“好胆固醇”。它参与脂质的逆向转运。流行病学研究发现HDL-C与冠心病(CHD)风险呈负相关。根据HDL-C水平分组时,HDL-C高于60mg/dL的受试者患冠心病的风险低于HDL-C为40 - 60mg/dL的受试者,而后者又低于HDL-C低于40mg/dL的受试者。尚未确定HDL-C对冠心病风险产生有益作用的上限。治疗低HDL-C患者的目标尚未明确确立。尽管已知许多药物可提高HDL-C浓度,但他汀类药物已被证明可降低冠心病风险和死亡率。胆固醇酯转运蛋白(CETP)参与HDL-C的代谢,其抑制剂正在积极进行临床应用筛选。然而,CETP抑制剂的最终答案仍有待揭晓。